MJFF Partners to Assess Clinical Development of Nilotinib in Parkinson's Disease
In preliminary studies, the cancer drug nilotinib has shown potential as a treatment for Parkinson's disease, but more research is needed to further test safety and long-term use.
MJFF, Van Andel Research Institute and Cure Parkinson's Trust announced plans to collaborate on the clinical assessment of nilotinib as a potential treatment for PD. Read more about this drug and its cautionary promise for Parkinson's disease, then join us for a webinar with further discussion.
The Michael J. Fox Foundation
Grand Central Station, P.O. Box 4777
New York, NY 10163-4777